Baker Bro adds to BCRX

Baker Bro adds to BCRX

Baker Bros. Advisors LP came out with a freshly-submitted 13D filing with the SEC, biotech-focused Baker Bros. Advisors LP, founded by Julian and Felix Baker, currently owns a stake of 14.33 million shares in BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX). . Baker Bro adds to BCRX

This is an almost 20% increase in Baker Bros. stake in BCRX. As you may know, we have followed BCRX since its IPO more years ago than we want to admit.

The affair with BCRX has been one similar to a marriage. We have witnessed the “short needle fiasco”, we have seen the company shares get squeezed many years ago that you will see if you go back in time on a long term chart.

We have seen the company finally get a drug approved only to see sales that are less than impressive.

With this being said we like the technology, we like the way the company goes about finding a cure.

We know the price of borrowing money will not stay this low for infinity. We know that more M&A’s are coming. We want to position ourselves in companies that we can tolerate buyout or not. We want you to get to know a handful of names you believe in and learn how they trade. This is a sure fire way to wealth creation.

Back to BCRX. Baker Bros is one of the most respected investors in the space. As stated by the aforementioned public filing, Baker Bros. Advisors, which holds these shares for investment purposes only, might make suggestions to the company’s management regarding financing, but may also change their present intentions. It appears that this activist filing stands behind the stock’s surge of more than 4% in Friday’s post-market trading session. Meanwhile, the drug maker that develops novel small molecule drugs aimed at blocking key enzymes involved in rare diseases has seen its shares drop 24% year-to-date.

BCRX has seen an increase in the number of hedge funds of late from a number of 16 to 25. These funds now own over 31% of the company.

Put BCRX on your radar, get to know it. learn how it trades. We can’t tell you everything you need to know in one article. Know we like this name as you can see from old alerts.

We are not saying rush out to buy BCRX today. We are saying get to know a good handful of companies. Know them well. Know how they trade. Then you will have the confidence to buy a stock while others are selling.

Stay Nimble

Stay Smart

 

 

 

 

 

The biotech stock received more attention from the hedge funds monitored by the Insider Monkey team during the second quarter. The number of hedge funds invested in BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) increased to 25 from 16 quarter-over-quarter, accumulating 31.80% of the company’s shares. Similarly, the value of their investments increased to $343.28 million from $234.51 million during the three-month period. Peter Kolchinsky’s RA Capital Management held a 2.61 million position in BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) at the end of the second quarter. Baker Bro adds to BCRX